Trick and treat: Ambushing recurrent tumors before they get out of the door

Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.